NANOBIOTIX
Nanobiotix is a French biopharmaceutical company specializing in nanotechnologies applied to oncology. It develops innovative treatments aimed at enhancing the efficacy of radiotherapy through nanoparticles that locally amplify the effects of radiation. Its lead candidate, NBTXR3, is in clinical development for several types of cancer. The company positions itself at the forefront of precision medicine and physical anti-cancer therapies.
Price history of NANOBIOTIX
Price history of NANOBIOTIX
Performance & Momentum
Nanobiotix Joins CAC Mid 60 and SBF 120 on Euronext Paris
Nanobiotix recently joined the CAC Mid 60 and SBF 120 indices, enhancing its visibility on Euronext Paris. This inclusion reflects the stock's significant progress, having doubled in value over three months and rising nearly 500% annually. The company also secured $71 million in non-dilutive funding to support its oncology clinical development, partnering with renowned institutions such as MD Anderson and Johnson & Johnson. These advances strengthen its position and could boost investor interest over the medium to long term.
Strategic Analysis
NANOBIOTIX • 2026
Nanobiotix is a French nanomedicine biotech focused on oncology, with a differentiated approach aimed at enhancing the effectiveness of radiotherapy rather than replacing it. Its positioning is built around a flagship candidate with strong scientific intensity, offering potentially broad clinical promise if development milestones are confirmed.
- Disruptive technology in oncology with a mechanism of action distinct from conventional approaches
- Positioning around a major medical need in optimizing radiotherapy-based treatments
- High clinical and strategic leverage potential if data continue to support the lead program
- Heavy dependence on a single lead clinical asset, concentrating development risk
- Biotech profile still highly exposed to regulatory, clinical, and financing uncertainty
Momentum is exceptionally strong and reflects a clear resurgence in market interest, with a very marked recovery trend across multiple time horizons. This rise suggests a re-rating of expectations around the story, but it also implies high sensitivity to any clinical or regulatory news, in a context where the valuation already appears to embed a great deal of optimism.
Similar stocks to NANOBIOTIX
Recent News
NANOBIOTIX
Major Change to Nanobiotix-Janssen Deal
1 year agoNanobiotix rose sharply by 10.17% on the SRD market after changes to its agreement with Janssen. The biotech, which focuses on nanoparticle-based cancer treatments, is now no longer required to fund the Nanoray-312 study for its NBTXR3 product, but it gives up some future upside. The market's positive reaction may reflect optimism over the resulting cost cuts and potentially a longer-term strategic investment.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
